

Emerging Biomarkers for Diagnosing Autoimmune Diseases

Mohammed Salah Hussein^{1,2}, Dr. Tamem Masnad Almasnad³, Osama Humaidi Alshamari⁴, Areej Mohammed Ibrahim⁵, Alharthi, Nawaf Hamed S⁶, Othman Omar Amodi⁷, Yara Hisham Alkowaileet⁸, Rahaf Abdullah Alruqi⁸, Meaad Abdullah Alshehri⁸, Shikhah Mohammed Alzayed⁹, Mazen Hamad Almakrami¹⁰

¹*Department of gastroenterology and endoscopy, Dr Samir Abbas Hospital, Jeddah, Saudi Arabia;*

²*Department of internal medicine, Faculty of medicine, Alazhar University hospitals, Cairo, Egypt*

³*General physician, Internal medicine resident, King Salman Hospital, Saudi Arabia*

⁴*General physician, King Abdulaziz Specialist Hospital, Aljouf, Saudi Arabia*

⁵*Medical intern, College of Medicine, King Abdulaziz University, Saudi Arabia*

⁶*General practitioner, Taif University, Saudi Arabia*

⁷*General physician, ER resident, Al-Kamil General Hospital, Saudi Arabia*

⁸*Medical intern, College of Medicine, King Saud Bin Abdulaziz University for Health Sciences, Jeddah, Saudi Arabia*

⁹*General physician, Prince Mutaib bin Abdulaziz Hospital, Aljouf, Saudi Arabia*

¹⁰*Family Medicine, Alsarrar PHC, Saudi Arabia*

Email: dr_msalahali@yahoo.com

Abstract: Autoimmune diseases represent a complex group of disorders characterized by an aberrant immune response, leading to tissue damage and dysfunction. Traditional diagnostic methods often rely on clinical symptoms and a limited panel of serological tests, which may not capture the full spectrum of the disease, particularly in early stages. Recent advances in the field of immunology and molecular biology have paved the way for the discovery of emerging biomarkers, which hold the potential to enhance diagnostic accuracy and facilitate early intervention. By investigating a range of biological samples, including blood, saliva, and tissue biopsies, researchers are uncovering novel protein signatures, genetic polymorphisms, and autoantibodies that may serve as reliable indicators of autoimmune conditions. The integration of emerging biomarkers into clinical practice could transform the diagnostic landscape for autoimmune diseases, allowing for more personalized treatment strategies. Current research focuses on specific biomarkers associated with common autoimmune disorders such as rheumatoid arthritis, lupus, and multiple sclerosis. This study aims to synthesize existing literature and experimental findings on potential biomarkers, assess their sensitivity and specificity, and evaluate their role in distinguishing between different autoimmune conditions. By highlighting the most promising avenues for biomarker research, this study contribute to the development of targeted diagnostic tools that can improve patient outcomes and facilitate a more nuanced understanding of autoimmune disease mechanisms.

Keywords: Autoimmune diseases, biomarkers, diagnosis, immunology, molecular biology, serum biomarkers.

1. Introduction

Autoimmune diseases, wherein the body's immune system erroneously targets its own tissues, represent a significant and growing public health concern. With an estimated prevalence ranging from 2% to 5% across various populations, autoimmune disorders encompass a diverse array of conditions, including but not limited to rheumatoid arthritis, lupus erythematosus, multiple sclerosis, and type 1 diabetes [1]. The etiology of autoimmune diseases is multifaceted, involving genetic predispositions, environmental triggers, and dysregulated immune responses. Despite advancements in our understanding of these complex disorders, a considerable challenge continues to lie in their accurate and timely diagnosis [2]. Traditional diagnostic methods often rely on clinical symptoms and established serological markers that can be nonspecific or absent in early stages of disease, leading to delays in treatment commencement and potential for irreversible damage. Consequently, there is an urgent need for innovative approaches to enhance diagnostic accuracy—a field within which emerging biomarkers hold substantial promise [3].

Biomarkers, defined as biological indicators or substances measured in biological fluids or tissues, play an essential role in the diagnosis, prognosis, and monitoring of diseases. Within autoimmune disease research, biomarkers can reflect underlying pathological processes, assist in distinguishing between autoimmune conditions, and provide insight into disease activity and response to treatment [4]. Historically, the discovery and validation of biomarkers have been challenging, often involving a laborious process of correlating clinical manifestations with laboratory findings. However, advances in high-throughput technologies, such as genomics, proteomics, metabolomics, and bioinformatics, have catalyzed the exploration of novel biomarkers, allowing researchers to identify new candidates that may be more representative of the underlying pathophysiology of autoimmune diseases [5].

Recent studies have identified emerging biomarkers that are showing potential for improving the diagnostic landscape of autoimmune diseases. For instance, specific autoantibodies—such as anti-citrullinated protein antibodies (ACPAs) in rheumatoid arthritis—have demonstrated enhanced specificity and sensitivity over traditional markers like rheumatoid factor [6]. Moreover, the advent of novel imaging techniques and the incorporation of artificial intelligence into diagnostic procedures are aiding in the identification of distinct biomarker profiles that can clarify the clinical picture. The shift towards a more precision medicine-oriented approach is evident, as researchers explore the correlations between genetic variations (single nucleotide polymorphisms), cytokine profiles, and disease outcomes to discover more targeted diagnostic tools [7].

Furthermore, the integration of multi-omics approaches—considering the interplay among genomics, proteomics, and metabolomics—is beginning to shed light on the complex biological interactions underlying autoimmune disorders. For instance, changes in metabolite levels reflecting metabolic dysregulation may reveal pathophysiological mechanisms, offering new diagnostic avenues that go beyond traditional serological testing. The development of high-density protein microarrays has allowed for the simultaneous measurement of numerous biomarkers, paving the way for the identification of disease-specific signatures that can improve diagnostic accuracy [8].

It is also essential to consider the diverse manifestations of autoimmune diseases, as the same disorder may present with varied clinical symptoms across different populations. This variability underscores the necessity for biomarkers that can be universally applicable yet sensitive enough to capture the nuances of individual cases. Advances in machine learning and data analytics provide unprecedented opportunities to analyze large datasets derived from

multi-omics research and clinical cohorts, thus identifying biomarkers with the potential for widespread application in clinical diagnostics [9].

Moreover, a discussion of ethical considerations is warranted as researchers continue to pioneer the development and application of emerging biomarkers. Issues surrounding data privacy, informed consent, and the accessibility of biomarker testing must be taken into account as the field evolves. Ensuring that advancements in biomarker diagnostics do not exacerbate health disparities will be essential in promoting equitable healthcare solutions [10].

Current Diagnostic Approaches:

The traditional diagnostic approach to autoimmune diseases typically involves a thorough clinical assessment followed by a series of laboratory tests. The diagnostic process often includes the following steps [2]:

1. **Clinical Evaluation:** The initial step in diagnosing an autoimmune disease involves a comprehensive medical history and physical examination. Physicians look for specific symptoms, such as fatigue, joint pain, skin rashes, or organ dysfunction, which may suggest an autoimmune process. The presence of symptoms can guide the physician toward specific autoimmune diseases [4].
2. **Serological Testing:** Blood tests play a crucial role in diagnosing autoimmune diseases. Common serological tests include:
 - o **Antinuclear Antibody (ANA) Test:** This test screens for the presence of autoantibodies that target the nucleus of cells. A positive ANA test may indicate autoimmune diseases such as systemic lupus erythematosus (SLE) or Sjögren's syndrome, but it is not definitive for any single disease [7].
 - o **Specific Autoantibody Tests:** Depending on the suspected disease, specific autoantibodies may be tested. For instance, anti-dsDNA and anti-Smith antibodies are associated with lupus, while rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPA) are used in diagnosing rheumatoid arthritis [9].
 - o **Complement Levels:** Complement proteins are part of the immune system, and their levels can indicate disease activity in conditions like lupus [6].
3. **Imaging Studies:** Imaging techniques, such as X-rays, ultrasound, or MRI, may be employed to assess joint damage or organ involvement, particularly in diseases like rheumatoid arthritis or systemic sclerosis [10].
4. **Tissue Biopsies:** In certain cases, a biopsy of affected tissues may be necessary to confirm a diagnosis. For example, skin biopsies can help diagnose conditions like dermatomyositis or lupus erythematosus [11].

Despite their utility, traditional diagnostic methods for autoimmune diseases have several limitations that can hinder accurate and timely diagnosis:

1. **Non-Specificity of Symptoms:** Many autoimmune diseases share common symptoms, such as fatigue, joint pain, and fever. This overlap can lead to misdiagnosis or delayed diagnosis, as physicians may attribute symptoms to more common conditions or even to psychological factors [12].
2. **Variable Presentation:** Autoimmune diseases can manifest differently in different individuals, and symptoms may not follow a predictable pattern. This variability complicates the diagnostic process, as physicians may not recognize the underlying autoimmune process [13].
3. **Limitations of Serological Tests:** While serological tests are valuable, they are not always definitive. For example, a positive ANA test can be found in healthy individuals as well as in patients with various autoimmune diseases, leading to potential false positives. Similarly, the absence of specific autoantibodies does not rule out an autoimmune disease [14].

4. **Time-Consuming Process:** The traditional diagnostic approach can be lengthy, often requiring multiple visits to healthcare providers, extensive testing, and the exclusion of other conditions. This delay can lead to disease progression and increased morbidity [14].
5. **Potential for Overlap Syndromes:** Patients may present with features of multiple autoimmune diseases, known as overlap syndromes. This complexity can confuse the diagnostic process, as it may not be clear which disease is primary and which is secondary [11].
6. **Economic and Accessibility Barriers:** Access to advanced diagnostic testing may be limited in certain geographical areas or among specific populations. Economic factors can also hinder patients from obtaining necessary tests, leading to disparities in diagnosis and treatment [15].

Types of Emerging Biomarkers in Autoimmunity

I. Proteomic Biomarkers

Proteomics, the large-scale study of proteins, provides significant insights into the molecular underpinnings of autoimmune diseases. Proteomic biomarkers involve the identification and quantification of proteins that can signal disease presence or progression. In autoimmune conditions, these biomarkers can emerge from alterations in protein expression due to inflammatory processes or immune dysregulation [16].

1. **Protein Profiles:** Specific patterns of protein expression can be associated with different autoimmune diseases. For instance, elevated levels of cytokines—such as interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF- α)—are frequently observed in inflammatory conditions like rheumatoid arthritis. Measuring these cytokines through proteomic techniques can serve as important biomarkers for diagnosing and monitoring disease activity [17].
2. **Post-translational Modifications (PTMs):** Many proteins undergo PTMs that can significantly alter their function. In the context of autoimmunity, certain PTMs are associated with disease mechanisms. For example, citrullination of proteins, a process that converts arginine residues to citrulline, is crucial in rheumatoid arthritis and can lead to the generation of specific autoantibodies known as anti-citrullinated protein antibodies (ACPAs). Detection of these modifications can guide diagnosis and therapeutic decisions [18].
3. **Metabolic Profiling:** Metabolomic approaches have revealed differences in metabolic profiles between healthy individuals and those with autoimmune diseases. For instance, altered levels of metabolites involved in immune regulation may indicate susceptibility to or severity of autoimmune conditions. These insights can help develop targeted therapies, as well as strategies for disease prevention [19].

II. Genomic Biomarkers

The genomic landscape of autoimmune diseases encompasses variations in DNA that contribute to disease susceptibility, progression, and therapeutic response. Genomic biomarkers include single nucleotide polymorphisms (SNPs), copy number variations (CNVs), and gene expression profiles [11].

1. **Genetic Susceptibility:** Certain genetic variants are associated with increased risk for specific autoimmune diseases. For example, the HLA-DRB1 gene is linked to susceptibility in rheumatoid arthritis, while variations in the CTLA-4 gene have been implicated in type 1 diabetes. Identifying these genetic markers can aid in understanding an individual's risk and pave the way for early intervention strategies [20].
2. **Expression Profiles:** Gene expression profiling using technologies such as microarrays or RNA sequencing has unveiled distinct expression patterns associated with autoimmune diseases. These profiles can provide insights into disease mechanisms, inform prognosis, and predict therapeutic responses. For example, differential expression of immune-related

genes in systemic lupus erythematosus (SLE) patients may distinguish those at risk of severe flares [21].

3. **Epigenetic Modifications:** The role of epigenetics in autoimmunity is gaining traction, as it encompasses modifications in gene expression without alterations to the underlying DNA sequence. Methylation patterns and histone modifications can be influenced by environmental factors, leading to aberrant immune responses. Understanding these epigenetic changes can shed light on disease pathogenesis and uncover novel therapeutic targets [22].

III. Autoantibody Biomarkers

Autoantibodies are perhaps the most well-characterized biomarkers in autoimmune diseases. These antibodies target self-antigens and can serve as early indicators of autoimmune dysregulation [4].

1. **Specificity and Sensitivity:** Unlike other biomarkers, the presence of autoantibodies can provide direct evidence of autoimmune activity. For example, antinuclear antibodies (ANAs) are widely used as markers for SLE, while antibodies to double-stranded DNA (anti-dsDNA) are associated with disease activity in this condition. The specificity and sensitivity of these autoantibodies make them invaluable in diagnosing and monitoring autoimmune diseases [23].
2. **Profiles and Combinations:** Different autoimmune diseases manifest distinct autoantibody profiles. For example, anti-citrullinated peptide antibodies (ACPAs) are primarily associated with rheumatoid arthritis, while antibodies to the Jo-1 antigen may be found in idiopathic inflammatory myopathies. The combination of multiple autoantibodies can enhance diagnostic accuracy and provide insights into disease subsets, which is essential for tailoring treatment approaches [24].
3. **Predictive Markers:** Emerging research suggests that certain autoantibodies can also predict disease onset in at-risk populations. For instance, in type 1 diabetes, the presence of multiple autoantibodies can signify impending disease manifestation years before clinical symptoms appear. This predictive capacity highlights the potential for targeted interventions in preclinical stages of autoimmune diseases [25].

The Importance of Biomarkers in Autoimmunity

1. Enhancing Diagnosis and Distinguishing Conditions

Autoimmune diseases often share overlapping symptoms, making accurate diagnosis challenging. Patients may present with fatigue, joint pain, and skin rashes, symptoms that can be attributed to multiple disorders such as rheumatoid arthritis, lupus, and multiple sclerosis. Biomarkers provide critical diagnostic clarity in these instances [26].

For example, the presence of specific autoantibodies—like anti-nuclear antibodies (ANAs) in systemic lupus erythematosus (SLE)—can significantly aid in diagnosing this condition. Likewise, the presence of rheumatoid factor (RF) and anti-citrullinated protein antibodies (ACPAs) is instrumental in diagnosing rheumatoid arthritis. By utilizing these biomarkers, healthcare providers can make informed decisions, leading to more accurate diagnoses and timely interventions [27].

2. Evaluating Disease Activity and Prognosis

Biomarkers can provide insight into the activity level of autoimmune diseases, which can fluctuate over time. Measuring certain cytokines, such as interleukins or tumor necrosis factor-alpha (TNF- α), can indicate the level of inflammation and help assess disease activity. For instance, elevated TNF- α levels in conditions like Crohn's disease can suggest a more active form of the disease, influencing treatment decisions such as the use of biologic therapies [28].

Furthermore, prognostic biomarkers can give clinicians valuable information about potential disease progression. For example, patients with specific genetic markers may have a

higher risk for severe disease or complications. Understanding these risks allows healthcare providers to implement proactive monitoring strategies and tailor treatments accordingly [29].

3. Guiding Treatment Decisions

Personalized medicine is increasingly becoming a cornerstone of modern healthcare, particularly in the management of autoimmune diseases. Biomarkers are integral to this movement, as they help identify the most effective therapeutic options for individual patients [30].

For instance, in patients with rheumatoid arthritis, various genetic biomarkers can predict response to methotrexate or biologic therapies. In multiple sclerosis, the presence of antibodies against the drug interferon-beta may predict potential resistance to this treatment. By selecting therapies based on biomarker profiles, clinicians can enhance treatment efficacy, minimize adverse side effects, and improve patient quality of life [31].

4. Monitoring Therapeutic Efficacy and Disease Recurrence

Biomarkers are essential tools for monitoring disease response to therapeutic interventions and predicting recurrence. Regular assessment of specific biomarkers can help clinicians determine whether a treatment is effective or needs adjustment. In conditions like systemic sclerosis, the measurement of serum levels of certain biomarkers can indicate fibrosis progression, prompting changes in management strategy before significant organ damage occurs [32].

Additionally, biomarkers may alert healthcare providers to imminent flares in autoimmune diseases. For instance, elevated levels of autoantibodies in patients with lupus can precede clinical exacerbations, allowing caregivers to implement preventive measures. This proactive monitoring is crucial in enhancing patient outcomes and minimizing the impacts of potential disease flares [30].

Opportunities and Challenges

Recent advancements in biomarker discovery have led to the identification of several emerging biomarkers that could significantly improve the diagnostic and therapeutic landscape for autoimmune diseases. These include cytokine profiles, genetic markers, and even epigenetic modifications. Cytokines such as interleukin (IL)-6 and IL-17 have gained attention due to their roles in the pathogenesis of autoimmune diseases. Detecting elevated levels of these cytokines could refine diagnostic criteria, facilitate early detection, and aid in monitoring disease activity and treatment response [32].

Genetic biomarkers, including specific single nucleotide polymorphisms (SNPs), have also been identified as risk factors for autoimmune diseases. For example, the presence of particular HLA alleles has been associated with increased susceptibility to conditions like rheumatoid arthritis and ankylosing spondylitis. Incorporating genetic testing into clinical practice can help identify at-risk individuals, allowing for early intervention and personalized treatment strategies [33].

Despite the potential promise of these emerging biomarkers, several challenges must be addressed before they can be seamlessly integrated into clinical practice. Variability in biomarker expression, differences in assay techniques, and the potential for false positives and negatives necessitate robust validation studies. Moreover, ethical considerations surrounding genetic testing and biomarker identification must be navigated carefully to ensure patient comfort and confidentiality [34].

The integration of emerging biomarkers into diagnostic practices promises several transformative opportunities. Firstly, it can facilitate more accurate and timely diagnoses, reducing the duration of the diagnostic odyssey faced by many autoimmune patients. Enhanced diagnostic precision may help clinicians distinguish between overlapping autoimmune conditions, leading to increased confidence in treatment decisions. This is particularly relevant

in diseases like Systemic Lupus Erythematosus (SLE), where many patients present with overlapping symptoms but may require vastly different treatment approaches [35].

Furthermore, biomarkers can support the implementation of stratified medicine, where treatment regimens are tailored according to individual biomarker profiles. Increased specificity in diagnosis does not only improve therapeutic outcomes but also minimizes the risks associated with overtreatment or mismanagement of patients [36].

The influence of emerging biomarkers extends beyond diagnostics into the realm of patient management. Monitoring disease activity and treatment response is integral to managing autoimmune diseases effectively. Traditional measures often rely on subjective assessments and general laboratory results, which may not accurately reflect the underlying disease state. In contrast, biomarkers can provide objective endpoints to gauge disease status and guide therapy [37- 39].

For instance, in rheumatoid arthritis, the use of biomarkers such as C-reactive protein (CRP) or erythrocyte sedimentation rate (ESR) is common to evaluate inflammation [40]. However, emerging biomarkers that reflect specific pathophysiological processes may offer insights into mechanisms behind treatment failures [41, 42]. For example, if a patient's biomarker profile indicates persistent high levels of pro-inflammatory cytokines despite treatment, clinicians might consider alternative therapies, such as biologics specifically targeting those cytokines [43].

Moreover, biomarkers can serve as predictors of treatment efficacy, allowing clinicians to adopt a more proactive approach to therapy. Identifying which patients are likely to respond favorably to specific treatments can enhance patient outcomes and resource management, ultimately leading to more efficient healthcare systems [44].

2. Conclusion:

The exploration of emerging biomarkers for diagnosing autoimmune diseases presents a promising frontier in enhancing diagnostic precision and improving patient management. The integration of novel biomarkers into the clinical framework has the potential to revolutionize our understanding of autoimmune pathologies, enabling early detection and tailored therapeutic approaches. As research progresses, the identification of specific proteins, genetic variants, and autoantibodies will not only facilitate more accurate diagnoses but also aid in distinguishing between different autoimmune conditions, thus preventing misdiagnosis and ensuring timely intervention.

However, the journey towards clinical implementation requires rigorous validation of these biomarkers, addressing existing challenges such as reproducibility and standardization in diverse populations. Collaborative efforts among researchers, clinicians, and regulatory bodies will be essential to overcome these obstacles and bring these innovations to the forefront of healthcare practice. Ultimately, continuous investment in biomarker research and technological advancements will pave the way for a more nuanced understanding of autoimmune diseases, transforming the landscape of autoimmune diagnostics and improving outcomes for patients worldwide.

References

1. Autoimmune encephalitis with psychiatric features in adults: historical evolution and prospective challenge. Hansen N, Timäus C. *J Neural Transm (Vienna)* 2021;128:1–14. doi: 10.1007/s00702-020-02258-z.
2. Searching for autoimmune encephalitis: beware of normal CSF. Hébert J, Gros P, Lapointe S, et al. *J Neuroimmunol.* 2020;345:577285. doi: 10.1016/j.jneuroim.2020.577285.

3. A clinical approach to diagnosis of autoimmune encephalitis. Graus F, Titulaer MJ, Balu R, et al. *Lancet Neurol.* 2016;15:391–404. doi: 10.1016/S1474-4422(15)00401-9.
4. Autoimmune encephalitis: proposed best practice recommendations for diagnosis and acute management. Abboud H, Probasco JC, Irani S, et al. *J Neurol Neurosurg Psychiatry.* 2021;92:757–768. doi: 10.1136/jnnp-2020-325300.
5. Psychiatric manifestations of autoimmune encephalitis. Ford H, Griffith S, Warren N, et al. *Autoimmun Rev.* 2022;21:103145. doi: 10.1016/j.autrev.2022.103145.
6. Investigation of LGI1 as the antigen in limbic encephalitis previously attributed to potassium channels: a case series. Lai M, Huijbers MG, Lancaster E, et al. *Lancet Neurol.* 2010;9:776–785. doi: 10.1016/S1474-4422(10)70137-X.
7. Autoimmune encephalitis: presentation, diagnosis, and management. Lancaster E. *J Clin Neurol.* 2022;18:373–390. doi: 10.3988/jcn.2022.18.4.373.
8. Autoimmune encephalitis misdiagnosis in adults. Flanagan EP, Geschwind MD, Lopez-Chiriboga AS, et al. *JAMA Neurol.* 2023;80:30–39. doi: 10.1001/jamaneurol.2022.4251.
9. Seronegative autoimmune encephalitis: exploring the unknown. van Steenhoven RW, Titulaer MJ. *Brain.* 2022;145:3339–3340. doi: 10.1093/brain/awac338.
10. Faciobrachial dystonic seizures precede Lgi1 antibody limbic encephalitis. Irani SR, Michell AW, Lang B, et al. *Ann Neurol.* 2011;69:892–900. doi: 10.1002/ana.22307.
11. Mimickers of autoimmune encephalitis: a literature review. Alshutaihi MS, Mazketly M, Tabbakh M, Akkash N, Bahro T, Alsaman MZ. *J Int Med Res.* 2024;52:3000605241248050. doi: 10.1177/03000605241248050.
12. Management of suspected viral encephalitis in adults--Association of British Neurologists and British Infection Association National Guidelines. Solomon T, Michael BD, Smith PE, et al. *J Infect.* 2012;64:347–373. doi: 10.1016/j.jinf.2011.11.014.
13. Anti-N-methyl-D-aspartate receptor encephalitis: a severe, potentially reversible autoimmune encephalitis. Liu CY, Zhu J, Zheng XY, Ma C, Wang X. *Mediators Inflamm.* 2017;2017:6361479. doi: 10.1155/2017/6361479.
14. Autoantibodies detection in anti-N-methyl-D-aspartate receptor encephalitis. Li J, Wang Q, Wang H. *Ann Transl Med.* 2023;11:284. doi: 10.21037/atm-20-2279.
15. Clinical and MRI differential analysis of autoimmune encephalitis and viral encephalitis. Tan Y, Liu M, He L. *J Taibah Univ Med Sci.* 2023;18:271–278. doi: 10.1016/j.jtumed.2022.09.016.
16. Early-stage contactin-associated protein-like 2 limbic encephalitis: clues for diagnosis. Benoit J, Muñoz-Castrillo S, Vogrig A, et al. *Neurol Neuroimmunol Neuroinflamm.* 2023;10 doi: 10.1212/NXI.0000000000200041.
17. Anti-IgLON5 disease: a novel topic beyond neuroimmunology. Zhang YH, Ni Y, Gao YN, et al. *Neural Regen Res.* 2023;18:1017–1022. doi: 10.4103/1673-5374.355742.
18. Brain perfusion SPECT with 99mTc-HMPAO in the diagnosis and follow-up of patients with anti-NMDA receptor encephalitis. Suárez JP, Domínguez ML, Gómez MA, Portilla JC, Gómez M, Casado I. *Neurologia.* 2018;33:622–623. doi: 10.1016/j.nrl.2016.05.019.
19. The clinical spectrum of Caspr2 antibody-associated disease. van Sonderen A, Ariño H, Petit-Pedrol M, et al. *Neurology.* 2016;87:521–528. doi: 10.1212/WNL.0000000000002917.
20. LGI1-antibody encephalitis is characterised by frequent, multifocal clinical and subclinical seizures. Aurangzeb S, Symmonds M, Knight RK, Kennett R, Wehner T, Irani SR. *Seizure.* 2017;50:14–17. doi: 10.1016/j.seizure.2017.05.017.
21. Neuropsychiatric disorders due to limbic encephalitis: immunologic aspect. Kao YC, Lin MI, Weng WC, Lee WT. *Int J Mol Sci.* 2020;22 doi: 10.3390/ijms22010389.
22. Antibody titres at diagnosis and during follow-up of anti-NMDA receptor encephalitis: a retrospective study. Gresa-Arribas N, Titulaer MJ, Torrents A, et al. *Lancet Neurol.* 2014;13:167–177. doi: 10.1016/S1474-4422(13)70282-5.

23. Encephalitis and antibodies to dipeptidyl-peptidase-like protein-6, a subunit of Kv4.2 potassium channels. Boronat A, Gelfand JM, Gresa-Arribas N, et al. *Ann Neurol*. 2013;73:120–128. doi: 10.1002/ana.23756.
24. Expanding the clinical spectrum of anti-DPPX encephalitis: a multicenter retrospective study. Gao Y, Zhang Y, Chunyu H, et al. *Front Neurosci*. 2024;18:1379933. doi: 10.3389/fnins.2024.1379933.
25. DPPX antibody-mediated autoimmune encephalitis: the first case with breast cancer and review of the literature. Dai Y, Zheng Y, Zhu J, Ding J, Qiu K, Tang B. *Heliyon*. 2024;10:0. doi: 10.1016/j.heliyon.2024.e27413.
26. Complement in neurological disorders and emerging complement-targeted therapeutics. Dalakas MC, Alexopoulos H, Spaeth PJ. *Nat Rev Neurol*. 2020;16:601–617. doi: 10.1038/s41582-020-0400-0.
27. Role of 18F-FDG-PET imaging in the diagnosis of autoimmune encephalitis. Morbelli S, Djekidel M, Hesse S, Pagani M, Barthel H. *Lancet Neurol*. 2016;15:1009–1010. doi: 10.1016/S1474-4422(16)30140-5.
28. Encephalitis and GABAB receptor antibodies: novel findings in a new case series of 20 patients. Höftberger R, Titulaer MJ, Sabater L, et al. *Neurology*. 2013;81:1500–1506. doi: 10.1212/WNL.0b013e3182a9585f.
29. Encephalitis and AMPA receptor antibodies: novel findings in a case series of 22 patients. Höftberger R, van Sonderen A, Leypoldt F, et al. *Neurology*. 2015;84:2403–2412. doi: 10.1212/WNL.0000000000001682.
30. Clinical characteristics of anti-GABA-B receptor encephalitis. Zhu F, Shan W, Lv R, Li Z, Wang Q. *Front Neurol*. 2020;11:403. doi: 10.3389/fneur.2020.00403.
31. Anti-IgLON5 disease - the current state of knowledge and further perspectives. Madetko N, Marzec W, Kowalska A, Przewodowska D, Alster P, Koziorowski D. *Front Immunol*. 2022;13:852215. doi: 10.3389/fimmu.2022.852215.
32. Abnormal brain metabolism on FDG-PET/CT is a common early finding in autoimmune encephalitis. Probasco JC, Solnes L, Nalluri A, et al. *Neurol Neuroimmunol Neuroinflamm*. 2017;4:0. doi: 10.1212/NXI.0000000000000352.
33. The essential role of neuroimaging in diagnosing and managing cerebrovascular disease in Africa: a review. Aderinto N, Olatunji D, Abdulbasit M, Edun M. *Ann Med*. 2023;55:2251490. doi: 10.1080/07853890.2023.2251490.
34. Autoimmune encephalitis [Internet] Treasure Island (FL): StatPearls Publishing; 2024. Gole S, Anand A.
35. Cerebrospinal fluid findings in patients with autoimmune encephalitis—a systematic analysis. Blinder T, Lewerenz J. *Front Neurol*. 2019;10:804. doi: 10.3389/fneur.2019.00804.
36. Cerebrospinal fluid (CSF) analysis and interpretation in neurocritical care for acute neurological conditions. Hrishi AP, Sethuraman M. *Indian J Crit Care Med*. 2019;23:0–9. doi: 10.5005/jp-journals-10071-23187.
37. Anti-NMDA receptor autoimmune encephalitis: diagnosis and management strategies. Nguyen L, Wang C. *Int J Gen Med*. 2023;16:7–21. doi: 10.2147/IJGM.S397429.
38. Diffusion kurtosis imaging and diffusion tensor imaging parameters applied to white matter and gray matter of patients with anti-N-methyl-D-aspartate receptor encephalitis. Liu H, Xiang Y, Liu J, et al. *Front Neurosci*. 2022;16:1030230. doi: 10.3389/fnins.2022.1030230.
39. Disturbance of gut bacteria and metabolites are associated with disease severity and predict outcome of NMDAR encephalitis: a prospective case-control study. Gong X, Liu Y, Liu X, Li A, Guo K, Zhou D, Hong Z. *Front Immunol*. 2021;12:791780. doi: 10.3389/fimmu.2021.791780.

40. Serum and CSF neurofilament light chain levels in antibody-mediated encephalitis. Mariotto S, Gajofatto A, Zuliani L, et al. *J Neurol.* 2019;266:1643–1648. doi: 10.1007/s00415-019-09306-z.
41. Elevated CHI3L1 and OPN levels in patients with anti-N-methyl-d-aspartate receptor encephalitis. Zhao J, Wang C, Zhang Y, Sun R, Wang H, Li G, Zhang J. *J Neuroimmunol.* 2019;334:577005. doi: 10.1016/j.jneuroim.2019.577005.
42. White matter microstructural alterations in patients with anti-N-methyl-D-aspartate receptor encephalitis: a tract-based spatial statistics study. Wang X, Yin Y, Wang X, Xu G, Tian J, Ma X. *Mult Scler Relat Disord.* 2024;84:105500. doi: 10.1016/j.msard.2024.105500.
43. Typical metabolic pattern of (18)F-FDG PET in Anti-NMDAR encephalitis in the acute and subacute phases and its correlation with T2 FLAIR-MRI features. Yuan L, Mao G, Zhang Y, et al. *BMC Neurosci.* 2023;24:51. doi: 10.1186/s12868-023-00823-2.
44. Longitudinal measurement of cerebrospinal fluid neurofilament light in anti-N-methyl-D-aspartate receptor encephalitis. Macher S, Zrzavy T, Höftberger R, et al. *Eur J Neurol.* 2021;28:1401–1405. doi: 10.1111/ene.14631.